Efficacy of ezetimibe and future role in the management of refractory hyperlipidaemia in high-risk patients

British Journal of Cardiology

Volumn 15, Issue 4, 2008, Pages 205-209

  Sarwar, Rizwan ^a   Neuwirth, Clare ^b   Walji, Shahenaz ^b   Tan, Yvonne ^b   Seed, Mary ^c   Thompson, Gilbert R ^b   Naoumova, Rossi P ^b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Familial hypercholesterolaemia; LDL targets; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; CREATININE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MONOTHERAPY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 70349703967     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-76.
2. Coronary heart disease statistics, 2007 edition. British Heart Foundation Statistics Database. Available from: www.heartstats.org
3. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
4. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
5. Knopp RH, Gitter H, Truitt T et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-41. (Pubitemid 36458985)
6. National Institute of Health and Clinical Excellence. Ezetimibe for the treatment of primary (heterozygous-familial and nonfamilial) hypercholesterolaemia. London: NICE, 2007. Available from: http://www.nice.org. uk/guidance/ TA132
7. Department of Health. National Service Framework for coronary heart disease. Preventing coronary heart disease in high risk patients. London: Department of Health, 2000.
8. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991;303:893-6.
9. Civeira F. International panel on management of familial hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolaemia. Atherosclerosis 2004;173:55-68.
10. Joint British Societies. JBS2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91:1-52.
11. Tosi I, Toledo-Leiva P, Neuwirth C et al. Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in the Hammersmith Hospital Lipid Clinic. Atherosclerosis 2007;194:102-11. (Pubitemid 47464311)
12. Mikhailidis DP, Wierzbicki AS, Daskslopoulou SS et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005;21:959-69.
13. Pitsavos C, Skoumas I, Tousoulis D et al. The impact of ezetimibe and high-dose statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia. Int J Cardiol 2008. doi:10.1016/j.ijcard.2007.12.065.
14. Pisciotta L, Fasano T, Bellocchio A et al. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis 2007;194:e116-e122. (Pubitemid 47513100)
15. Stein E, Stender S, Mata P et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolaemia: efficacy and safety of ezetimibe coadministered with atorvastatin. Am Heart J 2004;148:447-55. (Pubitemid 39265117)
16. Simon JS, Karnoub MC, Devlin DJ et al. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics 2005;86:648-56.
17. Hegele AH, Guy J, Ban MR, Wang J. NPC1L1 haplotype is associated with inter-individual variation in plasma lowdensity lipoprotein response to ezetimibe. Lipids Health Dis 2005;4:16-21.
18. Naoumova RP, Marais AD, Mountney J et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis 1996;119:203-13. (Pubitemid 26029449)
19. Kastelein JJP, Akdim F, Stroes ESG et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43. (Pubitemid 351482735)
20. Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or ezetimibe? N Engl J Med 2008;358:1504-07.
21. Futterman LG, Lemberg L. Statin pleiotropy: fact or fiction? Am J Crit Care 2004;13:244-9. (Pubitemid 39456745)
22. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005;46:1855-62. (Pubitemid 41579807)
23. Drazen JM, Jarcho JA, Morrissey S, Curfman GD. Cholesterol lowering and ezetimibe. N Engl J Med 2008;358:1507-08.